Anat Achiron

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster et al. · Therapeutic Advances in Neurological Disorders · 2021 · 362 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Gait analysis in multiple sclerosis: Characterization of temporal–spatial parameters using GAITRite functional ambulation system

Uri Givon, Gabriel Zeilig, Anat Achiron · Gait & Posture · 2008 · 313 citations

Education, Neurology, Neuroscience +17

Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses

Anat Achiron, Uri Gabbay, R. Gilad et al. · Neurology · 1998 · 260 citations

Life Sciences, Neurology, Pharmacotherapy +16